Management of Stage 3 Hypertension with Proteinuria

First-Line Pharmacologic Management

The American College of Cardiology recommends starting an ACE inhibitor or ARB immediately and uptitrating to the maximum tolerated dose, targeting systolic blood pressure <120 mmHg, and restricting dietary sodium to <2.0 g/day in patients with stage 3 hypertension and proteinuria 1, 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that ACE inhibitors or ARBs are mandatory first-line therapy for patients with both hypertension and proteinuria, with aggressive uptitration to the maximum tolerated or FDA-approved daily dose for optimal antiproteinuric effect 1, 2, 3

The American Heart Association recommends targeting systolic blood pressure <120 mmHg using standardized office measurements in patients with proteinuria, as validated in the KDIGO guidelines 1, 2, 3

The National Kidney Foundation recommends restricting dietary sodium to <2.0 g/day (<90 mmol/day) in all patients with hypertension and proteinuria, as sodium restriction is synergistic with ACE inhibitor/ARB therapy and significantly enhances the antiproteinuric effect 1, 2, 3, 4, 5

The European Society of Cardiology recommends adding diuretics as the preferred second-line agent if blood pressure remains uncontrolled or volume overload is present in patients with hypertension and proteinuria 1, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest using potassium-wasting diuretics and/or potassium-binding agents to reduce serum potassium to normal, allowing continued use of RAS blockade in patients with hypertension and proteinuria 1, 2, 3, 6, 4, 5

The American College of Physicians recommends adding a mineralocorticoid receptor antagonist (spironolactone 25-50 mg daily) if proteinuria persists despite maximized ACE inhibitor/ARB and blood pressure control in patients with hypertension and proteinuria 2, 4, 5

The National Kidney Foundation recommends checking labs every 2-4 weeks initially, including serum creatinine, eGFR, potassium, and urine protein-to-creatinine ratio, and targeting proteinuria reduction of ≥25% by 3 months, ≥50% by 6 months in patients with hypertension and proteinuria 4, 5, 2

The American Heart Association recommends counseling patients to hold ACE inhibitor/ARB and diuretics during intercurrent illnesses or when at risk for volume depletion to prevent acute kidney injury in patients with hypertension and proteinuria 1, 2, 3

The European Society of Cardiology recommends normalizing weight, stopping smoking, and exercising regularly in patients with hypertension and proteinuria 1, 2, 4

The American College of Cardiology recommends considering statin therapy for persistent dyslipidemia, particularly in patients with other cardiovascular risk factors including hypertension 1, 3, 6, 5